Relationship between Receiving Authorities and Monitoring Authorities.
The EMEA experience

Brendan Cuddy
Inspections Sector, EMEA
Disclaimer

The views presented in this presentation are those of the author and should not be understood or quoted as being made on behalf of the EMEA and/or its scientific committees.
Agenda

• Introduction to EMEA & Centralised Procedure
• Introduction to work of EMEA Inspections Sector
• GLP Inspections in the Centralised procedure
• Conclusions
Introduction to EMEA & Centralised Procedure
What is the EMEA?

- One of the 15 independent European Community agencies
- Composed of a secretariat (EMEA staff), management board, scientific committees, working parties and expert groups (members nominated by EU/EEA Member States)
- Mobilises existing scientific and inspection resources of the EU/EEA for
  - evaluation of centralised medicinal products
  - preparing of guidelines on safety/quality/efficacy
  - coordination of verification of compliance with principles of GMP, GCP, GLP
How is the EMEA organised?

46 National Competent Authorities, plus NO, IS, LI + 4,000 European experts

EU institutions: Commission – Parliament - Council

Management Board

Committee for Herbal Medicinal Products (HMPC)

Committee for Human Medicinal Products (CHMP)

Committee for Veterinary Medicinal Products (CVMP)

Committee for Orphan Medicinal Products (COMP)

Paediatric committee (PDCO)
Where Does EMEA fit in?

“Europartnership”

- Evaluation of Centralised Marketing Authorisation Applications/variations - through CPMP/CVMP
- Evaluation of referrals/arbitrations (mutual recognition or national– through CPMP/CVMP
- Coordination of GMP/GLP/GCP – through supervisory authorities in Member States
- Sampling and testing of centrally authorised products – through OMCLs and supervisory authorities
- Working parties, expert groups – consist of experts nominated by Member States – 3000 experts
- Partnership with European Pharmacopoeia
Structure of the EMEA European Medicines Agency

Management Board
Executive Director
CPMP and working parties
CVMP and working parties
Financial controller
Directorate
COMP
Joint Quality Working Party and Inspectors’ Groups
EMEA Secretariat
Administration
Communications and Networking
Pre-authorisation Evaluation of Human Medicines
Post-authorisation Evaluation of Human Medicines
Veterinary Medicines and Inspections
National Competent Authorities

- Responsible for issuing and supervising national marketing authorisations (pharmacovigilance, inspections, sampling and testing)
- Authorisation of clinical trials on their territory
- Authorisation and supervision of manufacture and importation on their territory
- Supervision of GLP Test facilities
- Nominating members to EMEA Scientific Committees, working parties and other groups
Marketing Authorisation Systems

- Same dossier requirements
- Same requirements for Quality, Safety and Efficacy

4 Different authorisation possibilities:
- National
- Mutual recognition
- Decentralised procedure
- Centralised procedure
Centralised Procedure (CP) - Mandatory Scope (1)

Medicinal products developed by means of one of the following biotechnological processes:

- Recombinant DNA technology
- Controlled expression of gene coding for biologically active proteins
- Hybridoma and monoclonal antibody methods
CP - Mandatory Scope (2)

As of Nov. 2005, in addition mandatory for
- new active substances for the indications
  - diabetes
  - cancer
  - acquired immune deficiency syndrome (HIV)
  - neurodegenerative disorder (Alzheimer, ...)
  not licensed before coming into force of regulation EC 726/2004
- orphan medicinal products
Biosimilar Medicinal Products
(‘Biogenerics’)

... if biotechnological medicinal products

Mandatory for the Centralised Procedure
CP - Optional Scope (1)

• Products containing a new active substance not authorised before coming into force of the Regulation EC 726/2004

• Products constituting a significant therapeutic, scientific or technical innovation Will be evaluated on a case by case basis (consultation of two sponsors out of CHMP and, when needed, the relevant working parties)
CP - Optional Scope (2)

- Generic of a centrally authorised product
- Products which are in the interest of patients at community level:
  - Generic of a National/MRP product
  - Pandemic medicinal products
Centralised Procedure

- Submission of dossier to EMEA
- CXMP appoints rapporteur and co-rapporteur
- Rapporteur and co-rapporteur perform assessment and prepare draft assessment report
- All other CXMP members provide comments
- Adoption of CXMP opinions, final assessment report, summary of product characteristics

Decision by European Commission
Introduction to EMEA Inspections Sector
Main Activities of the EMEA Inspections Sector

• Good Manufacturing Practice (GMP)
• Good Clinical Practice (GCP)
• Good Laboratory Practice (GLP)
• Pharmacovigilance compliance verification
• PMF/VAMF inspections
• Mutual Recognition Agreements (MRA)
• Joint CHMP/CVMP Quality Working Party (QWP)
Main Activities of the EMEA Inspections Sector (2)

- EMEA Certification of Medicinal Products
- Sampling and Testing (S&T)
- Product Defects i.e. Quality problems
- GMP aspects of applications/validations
- Chair of GxP meetings
- Co-ordination of EudraCT and EudraGMP projects
GLP Inspections in the Centralised procedure
OVERVIEW OF CENTRALISED EVALUATION PROCEDURE

Pre-submission
- Validation of the MAA Dossier
  - Day 0

Primary Evaluation
- Day 70 Assessment Report

Pre-Authorisation
- Adoption of the Inspection Request
- Announcement to the Applicant (within 5 days since the adoption)
- Conduct of the Inspection
  - Final IR submitted to EMEA/CHMP by Day 180

Stop Clock
- Day 121

Secondary Evaluation
- Day 210

Post Authorisation
- GLP: Line Extensions
- Opinion
- Decision
- Post Authorisation
Product Specific Directives for Medicines

- **Legal Basis – Marketing Authorisation Applications**
  - **Human:**
    - 2003/63 Annex 1 Non-Clinical Introduction And General Principles
      - *(pharmaco-toxicological) studies shall be carried out in conformity with the provisions related to Good Laboratory Practice laid down in Council Directives 87/18/EEC on the harmonisation of regulations and administrative provisions relating to the application of the principles of good laboratory practice and the verification of their application for tests in chemical substances and 88/320/EEC on the inspection and verification of good laboratory practice (GLP)*
  - **Veterinary**
    - 2001/82 Annex 1 Part 3, Safety *and Residues* Testing
      - “Member states shall ensure that the tests are carried out in conformity with the provisions relating to good laboratory practice…”
Verification of compliance with GLP

• Legal Basis for Inspection during Assessment of MAA.
  – Regulation 726/2004 Article 57 (i)

• “co-ordination of the verification of compliance with the principles of good manufacturing practice, good laboratory practice, good clinical practice and the verification of compliance with pharmacovigilance obligations.”
EMEA SOP

• Procedure for co-ordinating GLP inspections of the
  – Pre-clinical studies
• Human and Veterinary applications.
• Pre-authorisation GLP inspections.
• Developed in collaboration with *ad hoc* GLP Inspectors Group
EMEA SOP

• Inspection requests triggered by assessors, prepared by EMEA and adopted by CxMP

• EEA Test Facility: GLP monitoring authority of MS where lab located & experts if nominated

• For 3\textsuperscript{rd} country Lab: GLP monitoring authority of (Co)- Rapporteur MS to provide inspection resources;

• Possibility for study audits and exceptionally facility audits
Evaluation of GLP Compliance

- The assessor is responsible for evaluating
  - the statements on GLP compliance provided in
    the application
  - the scientific content of each study.
- The assessor includes in the assessment report a standard statement that GLP audits are not considered necessary for the evaluation of the application or, if an audit is considered necessary, asks the inspections sector to prepare an inspection request for Day 90 or 120.
Adoption of Inspection request

- The IS circulates to the CxMP during the plenary meeting the GLP Inspection Request recommended by the Rapporteur and Co-Rapporteur.
- The CxMP adopts, rejects or postpones the recommended request.
Summary

• 1995 - 2003: 2 GLP Inspection Requests by CPMP
• 2004 - 2007: 6 GLP Inspection Requests by CHMP – study audits
• 2008 – 4 GLP Inspection Requests by CHMP – study audits
• 9 Marketing Authorisation Applications for medicines for human use
  – 9 Test facilities, 2 in EU, 4 in Canada, 3 in Non-OECD
  – c. 31 studies audited (&10 outstanding)
  – Inspection duration of 3 – 6 days
  – 29 studies so far found to be GLP compliant
  – 2 studies found to be not compliant with GLP (in full or partially)
Summary

• One study found to be not in compliance with GLP
• One study only partial non-compliance
• Minor deviations from GLP were observed in remainder of study audits
  – Integrity of study data was not jeopardised
• 27 studies were recommended to be used for the respective safety evaluation.
Inspection Findings

- Test facilities should pay particular attention to the difference between amendments and deviations, how and when each should be documented and how and when their impact on the study is evaluated by the Study Director.

- Study directors should ensure that GLP principles are adhered to when amendments and deviations to study reports are needed.
Inspection Findings

- The use and supervision of subcontractors in accordance with the GLP principles concerning multi-site studies.
- The role of Quality Assurance, and how the QA audits of studies are documented so that the types of inspections performed and the critical phases inspected are recorded.
Inspection Findings

• Lack of information regarding the determination of the homogeneity, concentration and stability of the test item prior to the commencement of the study.
Findings of non-compliance with GLP

- Findings of non-compliance with GLP should be used by the assessor as one piece of information to decide whether or not a study can be used in the application and in turn if the exclusion of a study affects the final opinion for the application.
Post-Authorisation

• A post authorisation inspection may be requested by a rapporteur/co-rapporteur to clarify any GLP issues that may arise after the authorisation has been granted.
EMEA Feedback

• GLP Inspections in Canada advised
  • It has come to our attention that Health Canada has not established a GLP compliance monitoring programme for Canadian laboratories that are engaged in the pre-clinical testing of medicinal products. Due to the uncertain GLP compliance status of pre-clinical studies originating from Canada, the EMEA Inspections Sector has advised the CHMP and CVMP that pivotal studies for centralised products should be inspected to assess their compliance with the Principles of GLP.

• OECD Guideline on Cross-contamination
Conclusions

• SOP has provided a comprehensive framework for CHMP to request GLP audits.
• SOP has provided a comprehensive set of standard documents for reference when preparing inspection, communicating outcome of inspection and preparing inspection report.
• Administrative aspects of inspections are easily dealt with.
  – All inspectorates approached have assigned resources to the inspections.
  – Inspections have been performed within the timeframe indicated in the inspection request and contract.
  – Performing and reporting the inspection by inspectorates has been done in accordance with procedure